SCHEMBL1133947

SCHEMBL1133947

COc1ncc(C=O)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48
TUBB3 Q13509 1/20 0.48
TUBB2A Q13885 1/20 0.48
TUBB8 Q3ZCM7 1/20 0.48
TUBA3E Q6PEY2 1/20 0.48
TUBA1A Q71U36 1/20 0.48
TUBA1C Q9BQE3 1/20 0.48
TUBB6 Q9BUF5 1/20 0.48
TUBB2B Q9BVA1 1/20 0.48
TUBB1 Q9H4B7 1/20 0.48
ALDH1A1 P00352 7/20 0.43
CYP2A6 P11509 1/20 0.43
KDM4E B2RXH2 2/20 0.42
FDPS P14324 1/20 0.41
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1133935 0.79 ALDH1A1 (0.43) ALDH1A1KDM4EL3MBTL1MAPTTDP1
SCHEMBL23677885 0.79 TUBB4A (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL5260855 0.77 TUBB4A (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2870003 0.76 TUBB4A (0.48) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29501241 0.76 KDM4E (0.59) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL27740854 0.76 GAA (0.43) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12701308 0.76 ALDH1A3 (0.48) ALDH1A1CYP2A6KDM4EFDPSL3MBTL1
SCHEMBL207440 0.76 KDM4E (0.59) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL20575433 0.74 ALDH1A1 (0.36) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13081282 0.74 TUBB4A (0.40) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118201911-A Compounds and their use as GPR183 inhibitors 南京艾美斐生物医药科技有限公司 2024-06-14 CN claimed
WO-2023066190-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) 2023-04-27 WO claimed
US-12624024-B2 EP2 antagonist compounds RESERVOIR NEUROSCIENCE, INC. (US) 2026-05-12 US disclosed
EP-4642450-A2 EP2 ANTAGONIST COMPOUNDS Reservoir Neuroscience, Inc. (US) 2025-11-05 EP disclosed
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-10-02 US disclosed
CN-120035593-A Pyrazine derivatives and uses thereof 福宏治疗公司 2025-05-23 CN disclosed
EP-4522279-A1 PYRAZINE DERIVATIVES AND USES THEREOF Foghorn Therapeutics Inc. (US) 2025-03-19 EP disclosed
US-20240300934-A1 COMPOUNDS FOR MODULATING MYCOBACTERIUM TUBERCULOSIS RESPONSE RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2024-09-12 US disclosed
WO-2024145259-A2 EP2 ANTAGONIST COMPOUNDS RESERVOIR NEUROSCIENCE, INC. (US) 2024-07-04 WO disclosed
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 US disclosed
US-20240182459-A1 EP2 ANTAGONIST COMPOUNDS RESERVOIR NEUROSCIENCE, INC. 2024-06-06 US disclosed
US-5428032-A Insecticides NIHON BAYER AGROCHEM K.K. (JP) 1995-06-27 US disclosed
EP-0605524-A1 ANTIBACTERIAL, ANTIMYCOPLASMAL COMPOUNDS RELATED TO MUPIROCIN SMITHKLINE BEECHAM PLC (GB) 1994-07-13 EP disclosed
US-5298507-A Insecticides NIHON BAYER AGROCHEM K.K. (JP) 1994-03-29 US disclosed
US-5204360-A Insecticides NIHON BAYER AGROCHEM K.K. (JP) 1993-04-20 US disclosed
WO-1993006118-A1 ANTIBACTERIAL, ANTIMYCOPLASMAL COMPOUNDS RELATED TO MUPIROCIN SMITHKLINE BEECHAM PLC (GB) 1993-04-01 WO disclosed
US-5001138-A Insecticides NIHON TOKUSHU NOYAKU SEIZO, K.K. (JP) 1991-03-19 US disclosed
US-4845106-A INSECTICIDES NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1989-07-04 US disclosed
US-4742060-A 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) 1988-05-03 US disclosed
EP-0192060-A1 Heterocyclic compounds NIHON BAYER AGROCHEM K.K. (JP) 1986-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300934-A1 COMPOUNDS FOR MODULATING MYCOBACTERIUM TUBERCULOSIS RESPONSE IFNG, NFATC1, RELA TUBB4A 293/4885TUBB 99/4885TUBA3C 1344/4885
US-12624024-B2 EP2 antagonist compounds PTGER1, PTGER2, PTGER4 TUBB4A 3091/4885TUBB 3646/4885TUBA3C 2597/4885
US-20240182459-A1 EP2 ANTAGONIST COMPOUNDS PTGER2, PTGER1, PTGES2 TUBB4A 4128/4885TUBB 4109/4885TUBA3C 3781/4885
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF BRCA1, VHL, SF3B5 TUBB4A 1261/4885TUBB 1180/4885TUBA3C 1346/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 TUBB4A 3803/4885TUBB 3700/4885TUBA3C 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.